Trials / Conditions / Agitation in Patients With Dementia of the Alzheimer's Type

Agitation in Patients With Dementia of the Alzheimer's Type

10 registered clinical trials studyying Agitation in Patients With Dementia of the Alzheimer's Type.

Status	Trial	Sponsor	Phase
Terminated	An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type NCT06736509	Axsome Therapeutics, Inc.	Phase 3
Completed	A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation NCT05557409	Axsome Therapeutics, Inc.	Phase 3
Completed	A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation NCT04947553	Axsome Therapeutics, Inc.	Phase 3
Completed	Assessing Clinical Outcomes in Alzheimer's Disease Agitation NCT04797715	Axsome Therapeutics, Inc.	Phase 3
Terminated	Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients W NCT04464564	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Terminated	Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients Wit NCT04408755	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quin NCT03393520	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Addressing Dementia Via Agitation-Centered Evaluation NCT03226522	Axsome Therapeutics, Inc.	Phase 2 / Phase 3
Terminated	Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients Wi NCT02446132	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3
Completed	Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the A NCT02442765	Otsuka Pharmaceutical Development & Commercialization, Inc.	Phase 3